In a 46-year-old female with sudden bilateral lower‑extremity weakness (motor strength 2/5) and absent plantar reflexes, after cauda equina syndrome and transverse myelitis have been ruled out, what is the immediate evaluation and management?

Guillain-Barré Syndrome (GBS) Evaluation and Management

This presentation is most consistent with Guillain-Barré syndrome (GBS), and you must immediately admit the patient, obtain urgent neurology consultation, initiate IV methylprednisolone 2-4 mg/kg/day, and strongly consider IVIG or plasmapheresis. 1, 2

Immediate Clinical Assessment

The combination of sudden bilateral lower extremity weakness (2/5 power) with absent plantar reflexes after excluding cauda equina and transverse myelitis strongly suggests an acute immune-mediated polyradiculoneuropathy. The "mute" (absent) plantar responses are critical—while GBS classically presents with areflexia, absent plantar responses specifically indicate peripheral nerve involvement rather than upper motor neuron pathology.

Key Diagnostic Features to Confirm

Motor examination specifics:

• Document if weakness is more proximal vs. distal
• Check for facial weakness or cranial nerve involvement (present in up to 50% of cases) 3, 4
• Assess respiratory function with vital capacity and negative inspiratory force—respiratory compromise can develop rapidly 1, 2, 4

Sensory examination:

• Look for distal paresthesias or "glove-and-stocking" sensory loss
• Check for loss of joint position sense 1
• Note that sensory symptoms may be atypical (described as "sharp zings" rather than typical numbness) 5

Autonomic assessment:

• Monitor for urinary retention, constipation, or ileus 1
• Check orthostatic vital signs
• Cardiac monitoring is essential—autonomic dysfunction can cause arrhythmias 1, 4

Preceding illness:

• Recent upper respiratory infection, gastroenteritis, or febrile illness within 1-4 weeks 3, 4, 5

Urgent Diagnostic Workup

Lumbar puncture (priority):

• CSF analysis for albuminocytological dissociation (elevated protein >60 mg/dL with normal cell count) 1, 3, 4
• Cell count and differential, glucose, gram stain, viral cultures/PCR to exclude infection 1, 2
• Cytology to rule out malignant cells 1

MRI spine with and without contrast:

• Already performed to exclude cauda equina/transverse myelitis, but review for nerve root enhancement which can occur in GBS 1

Electrodiagnostic studies:

• EMG and nerve conduction studies showing demyelinating polyneuropathy 1, 3
• These may be normal early in disease course—do not delay treatment if clinical suspicion is high

Laboratory screening:

• Serum testing: HbA1c, vitamin B12, TSH, vitamin B6, folate, CPK 1
• Ganglioside antibodies (anti-GQ1b, anti-GM1) 1, 6
• Consider HIV, Lyme, hepatitis B/C if risk factors present 1

Immediate Management Protocol

Grade 3-4 severity (your patient with 2/5 power):

1. Admit to monitored bed with continuous cardiac monitoring and frequent neurological checks 1, 2

2. Initiate IV methylprednisolone 2-4 mg/kg/day 1

   • Alternative: Pulse dosing with methylprednisolone 1 gram daily for 3-5 days 1, 2
   • Note: Steroids have limited evidence in idiopathic GBS but are reasonable in immune checkpoint inhibitor-related forms; given the severity, initiate while awaiting confirmatory testing 1

3. Strongly consider IVIG or plasmapheresis 1, 2, 4

   • Both are equivalent in efficacy
   • IVIG: Standard 5-day course 4
   • Start rapidly—do not delay for confirmatory testing if clinical suspicion is high

4. Respiratory monitoring:

   • Serial vital capacity and negative inspiratory force measurements 1, 4
   • Prepare for possible intubation if VC declining or NIF weakening
   • Respiratory failure is the leading cause of mortality

5. Supportive care:

   • DVT prophylaxis (high risk due to immobility)
   • Bowel regimen for constipation/ileus 1
   • Pain management with gabapentin, pregabalin, or duloxetine (avoid opioids) 1

Critical Pitfalls to Avoid

Do not wait for CSF results to initiate treatment—albuminocytological dissociation may not appear until 1-2 weeks after symptom onset. Clinical diagnosis drives immediate management 4.

Do not dismiss atypical features:

• Proximal rather than distal weakness can occur 5
• Facial diplegia without oculomotor involvement is possible 4
• Preserved or even brisk upper extremity reflexes early in disease 3
• Ataxia as a presenting feature 4

Monitor for rapid progression:

• GBS can worsen dramatically within 24-48 hours 4, 5
• Ascending weakness pattern means today's leg weakness becomes tomorrow's respiratory failure
• Serial examinations every 4-6 hours initially

Beware of diagnostic mimics:

• While cauda equina and transverse myelitis are ruled out, consider neurosarcoidosis if lymphadenopathy present 7
• Anti-GQ1b antibodies may indicate Miller Fisher variant or overlap syndromes 6
• Rare cases may have upper motor neuron signs (extensor plantars) creating diagnostic confusion 3

Expected Clinical Course

With appropriate treatment initiated at this stage (CESI/early CESR equivalent in GBS terms), expect slow improvement over weeks to months with intensive physical and occupational therapy 4. Most patients show initial stabilization within days of IVIG/plasmapheresis, followed by gradual motor recovery. However, 2/5 power indicates significant disease severity—prepare patient and family for prolonged rehabilitation.